心房颤动与促血栓状态:2020年重新审视Virchow三联征
该综述基于Virchow三联征(异常血液成分、血管壁异常、异常血流)框架,系统阐述心房颤动(AF)促血栓形成的多重机制。AF本身可激活凝血级联、增强血小板反应性并损害纤溶,且共病可放大这些过程;心房纤维化、内皮功能障碍及心房扩张伴心房收缩丧失共同促进血栓形成与栓塞。深入理解这些因素有助于改进AF临床风险分层和靶向治疗。
要点
- AF通过凝血激活、血小板高反应性和纤溶受损促进促血栓状态。
- 心房纤维化、内皮功能障碍和心房扩张伴收缩丧失共同构成血栓形成基质。
- 促血栓生物标志物(如血小板因子4、血管性血友病因子、纤维蛋白原、β-血栓球蛋白、D-二聚体)与AF血栓形成相关。
核心结论
- AF通过Virchow三联征涉及的多重机制增加病理性血栓形成风险,理解这些因素可改善临床风险分层和靶向治疗。
研究设计与样本
- 综述,基于Virchow三联征框架阐述AF促血栓状态机制。
主要发现
- AF本身增加凝血级联激活、血小板反应性和纤溶受损,共病可放大这些过程。
- 心房纤维化和内皮功能障碍与AF发生相关并促进心房重构,为血栓形成和栓塞提供平台。
- 心脏 chambers 扩张和心房收缩丧失导致血流减少,影像技术已证实。
- 血小板因子4、血管性血友病因子、纤维蛋白原、β-血栓球蛋白和D-二聚体等促血栓生物标志物被牵涉其中。
临床怎么用
- 临床可通过评估促血栓生物标志物和影像学心房结构功能改变来辅助AF风险分层。
- 针对凝血激活、血小板反应性和内皮功能障碍的靶向治疗可能改善AF管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) is characterised by an increased risk of pathological thrombus formation due to a disruption of physiological haemostatic mechanisms that are better understood by reference to Virchow's triad of 'abnormal blood constituents', 'vessel wall abnormalities' and 'abnormal blood flow'. First, there is increased activation of the coagulation cascade, platelet reactivity and impaired fibrinolysis as a result of AF per se, and these processes are amplified with pre-existing comorbidities. Several prothrombotic biomarkers including platelet factor 4, von Willebrand factor, fibrinogen, β-thromboglobulin and D-dimer have been implicated in this process. Second, structural changes such as atrial fibrosis and endothelial dysfunction are linked to the development of AF which promote further atrial remodelling, thereby providing a suitable platform for clot formation and subsequent embolisation. Third, these factors are compounded by the presence of reduced blood flow secondary to dilatation of cardiac chambers and loss of atrial systole which have been confirmed using various imaging techniques. Overall, an improved understanding of the various factors involved in thrombus formation will allow better clinical risk stratification and targeted therapies in AF.
引用
- Ding WY, Gupta D, Lip GYH, et al. Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. Heart. 2020. PMID: 32675218. doi:10.1136/heartjnl-2020-316977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。